Subscribe to:
Post Comments (Atom)
Third-party analyst just put a $1 billion price tag on this Nasdaq biotech’s lead drug
Vyome's lead drug is valued near 1 billion and the company is fully funded for Phase 3 with minimal dilution. ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ...
-
1. Earnings flood: Investors will hear from a slew of corporate titans on Thursday. Alibaba, Blackstone, Boston Scientific, Conoc...
-
The deadliest weekend of 2023 so far. Read Today's eNewspaper | Crosswords | ...
-
Friends, I invite you to join the upcoming 2026 Lent Retreat , led by Sr. Miriam James Heidland, in ...
No comments:
Post a Comment